NeuroOne Medical Technologies (NASDAQ:NMTC) Posts Quarterly Earnings Results, Beats Expectations By $0.30 EPS

NeuroOne Medical Technologies (NASDAQ:NMTC) announced its quarterly earnings data on Thursday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.30, FiscalAI reports. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 99.43%. The firm had revenue of $1.97 million for the quarter, compared to the consensus estimate of $2.55 million.

Here are the key takeaways from NeuroOne Medical Technologies’ conference call:

• Third-quarter product revenue rose 16% year over year to $2.0 million, while product orders increased 43% to $2.7 million. Gross margin also expanded to 59.9% from 53.9%, driven by a favorable product mix.
• Manufacturing constraints left a $1.7 million backlog and caused management to lower expected fiscal 2026 recognized revenue to $9.2 million-$10.5 million, despite approximately $11.2 million in expected orders. A second, larger manufacturing site is targeted for early 2027.
• NeuroOne received ISO 13485 certification, enabling international commercialization of its OneRF Brain Ablation, OneRF Trigeminal Nerve Ablation, and Evo diagnostic product lines. The company plans to work with Zimmer Biomet and independent distributors to enter selected markets.
• The company reported progress across its pipeline, including clinical support for OneRF in patients with existing neuromodulation implants, expansion of trigeminal nerve ablation distribution, and preclinical collaborations for the StereoCED drug-delivery platform. StereoCED is expected to be ready for investigational human studies by the end of September, while the BVNA back-pain system is targeted for a 510(k) submission in the second half of calendar 2027.
• Cash and equivalents declined to $2.0 million as of June 30 from $6.6 million at fiscal year-end, while the quarterly net loss widened to $2.0 million from $1.5 million. The company raised $0.4 million during the quarter and another $1.0 million after quarter-end through its ATM program, indicating continued reliance on equity financing.

NeuroOne Medical Technologies Stock Up 20.4%

NASDAQ:NMTC traded up $0.31 during trading hours on Thursday, reaching $1.83. The company had a trading volume of 296,705 shares, compared to its average volume of 52,849. The stock has a 50-day moving average of $2.57 and a two-hundred day moving average of $3.80. NeuroOne Medical Technologies has a one year low of $1.42 and a one year high of $6.96. The firm has a market capitalization of $15.92 million, a PE ratio of -2.15 and a beta of 0.61.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. LADENBURG THALM/SH SH raised their target price on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings upgraded NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, NeuroOne Medical Technologies currently has a consensus rating of “Hold” and a consensus price target of $11.67.

Insider Activity

In related news, Director Mark Christianson sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total transaction of $31,800.00. Following the sale, the director directly owned 20,692 shares in the company, valued at $65,800.56. This represents a 32.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NMTC. Goldman Sachs Group Inc. acquired a new position in NeuroOne Medical Technologies in the first quarter valued at about $84,000. XTX Topco Ltd bought a new position in NeuroOne Medical Technologies in the second quarter valued at approximately $51,000. Vanguard Group Inc. lifted its stake in NeuroOne Medical Technologies by 31.2% in the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after buying an additional 375,639 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of NeuroOne Medical Technologies in the third quarter valued at approximately $88,000. Finally, Susquehanna International Group LLP bought a new stake in shares of NeuroOne Medical Technologies during the third quarter worth $47,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.